According to the company, the new facility will provide significant capacity to further develop its global team, which it plans to grow by more than 100, with additional biostatisticians, statistical programmers and data managers expected to join the company by the end of 2017.
The new hires will be across locations in the US, Europe, and India.
Cytel also recently established a dedicated quantitative pharmacology and pharmacometrics team to meet an increasing demand for model-informed drug development for biopharma clients.
Model-informed drug development is an expanding area of focus within the company’s portfolio, Cecilia Fosser, director of the unit told us previously.
“By applying our combined software development, biostatistics, and pharmacometrics know-how we can efficiently provide answers to help answer critical research questions from early development through post registration,” she said.